News | June 10, 2022
GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer
Healthcare is timely and personal – and its delivery should be too
Healthcare is timely and personal – and its delivery should be too
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Based on a post hoc analysis, fewer required respiratory interventions
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Subscribe To Our Newsletter & Stay Updated
